six The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV during the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) such as bosentan, sitaxentan and ambrisentan are oral therapies licensed to be used in PAH. As no oral agent has demonstrated superiority there remains discussion concerning